Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and Longevity Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PRKAB1 scaffold subunit research and AMPK complex drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRKAB1 Full-Length, CBM-Domain Recombinant Protein & Trimeric Complexes High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 expressed. |
View PRKAB1 Products |
| Gene Delivery | PRKAB1 Promise-ORF Lentivirus Full-length ORF for stable cell line generation in metabolic disease models. |
View PRKAB1 Products |
| Benchmark Ab | Anti-PRKAB1 Recombinant Antibody Positive control for assay normalization (immunoblotting, kinase assays). |
View PRKAB1 Products |
| Isoform Control / Selectivity Counter-Screen | PRKAB2 (Beta 2 Isoform) Recombinant Protein For beta-1 vs beta-2 selectivity screening. Sequence Verified. Muscle-specific paralog. |
View PRKAB2 Products |
| Complex Partner | PRKAA1 (Alpha 1 Catalytic) Recombinant Protein Catalytic subunit for heterotrimeric complex reconstitution assays. |
View PRKAA1 Products |
| Regulatory Subunit | PRKAG2 (Gamma 2) Recombinant Protein For AMPK holoenzyme assembly and nucleotide-binding studies. |
View PRKAG2 Products |
| Related Target (Upstream) | STK11 (LKB1) Recombinant Protein Upstream master kinase critical for basal AMPK activation (Thr172 phosphorylation). |
View STK11 Products |
| Validator | PRKAB1 siRNA Set (3 unique sequences) For isoform-specific knockdown (>80% efficiency) and specificity verification. |
View PRKAB1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (β1 vs β2) | PRKAB1 and PRKAB2 ortholog proteins available with distinct C-terminal regions; >95% purity, Sequence Verified by Mass Spec. |
| Heterotrimeric Complex Reconstitution | Low-endotoxin (<1EU/µg) PRKAB1 scaffold compatible with PRKAA1/PRKAG2 co-incubation; preserves CBM structural integrity. |
| Carbohydrate Binding Module (CBM) Inhibition | CBM-domain specific construct (Glycogen-binding site intact) for small molecule displacement assays. |
| Allosteric Site (ADaM) Integrity | Co-expressed active trimeric complexes (α/β/γ) to preserve rational design pockets for allosteric modulators. |
| Assay Normalization & Benchmark Controls | High-purity Benchmark Antibodies included for immunoblotting and kinase assay baselines. |
| False Positives in Screening | Validated siRNA included for cellular pathway specificity checks; scrambled controls provided. |
Live PRKAB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Allosteric Activation Research
- ➤ Recent CBM-Targeting Patent Filings
- ➤ Latest Resistance Research
Global Clinical Landscape & Future Outlook
The race for PRKAB1-targeted therapeutics is intensifying, with a strategic pivot from pan-AMPK activation toward isoform-selective and tissue-specific modulation. First-generation direct activators (e.g., A-769662 analogs) faced challenges in muscle vs. liver selectivity. The next wave of R&D targets the PRKAB1 carbohydrate-binding module (CBM) to decouple glycogen sensing from kinase activation—potentially enabling metabolic benefits without disturbing cardiac glycogen stores. Meanwhile, major players are shifting focus from indirect, non-specific activators to direct small-molecule allosteric modulators that achieve high Beta-1 selectivity, particularly for metabolic dysfunction-associated steatohepatitis (MASH), diabetic nephropathy, and cardiovascular indications. The future landscape heavily prioritizes achieving robust efficacy in the liver while minimizing cardiac and skeletal muscle off-target effects. Emerging strategies also include combination with GLP-1 agonists for synergistic metabolic benefits and exploration in longevity/anti-aging indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Activators (α/β interface / ADaM site) | Merck, AstraZeneca, Pfizer, Poxel, vTv Therapeutics | Type 2 Diabetes, NAFLD, MASH, Diabetic Nephropathy | Heterotrimeric Complex Formation (Need PRKAB1+PRKAA1+PRKAG2 co-expression); Kinase Activity Assay (Need High-Purity Trimeric Proteins) |
| CBM-Targeted Small Molecules | University of Oxford, Novo Nordisk | Metabolic Syndrome, Obesity | CBM Domain Binding Assay (Need isolated PRKAB1 CBM protein >95% purity) |
| Isoform-Selective Biologics | Lilly, Pfizer | Cardiac Glycogenosis | β1 vs β2 Selectivity Screen (Need PRKAB1 and PRKAB2 purified proteins) |
| PROTAC (Degrader) | Academic / Biotech spin-offs | Oncology (Context-dependent) | Ternary Complex Validation (Need Precise PRKAB1 Monomers) |
| Gene Therapy (Liver-specific) | Various Biotech | Diabetes, Rare Metabolic Disorders | Stable Cell Line Construction (Need PRKAB1 Lentivirus for HepG2 models); Cellular Expression Tracking (Need Sequence-Verified ORF) |